Ping Tu
Impact in
-
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Diabetes Treatment and Management
- Diabetes Management and Research
-
- Bone health and osteoporosis research
Papers in
-
- Diabetes, Cardiovascular Risks, and Lipoproteins 6
-
- Chronic Kidney Disease and Diabetes 4
- Co-authors
- Peng Duan (13 shared papers)Jiang Liu (7 shared papers)Meilin Wei (2 shared papers)Yajun Lin (5 shared papers)Yong‐Zhan Zhen (4 shared papers)Yi Shao (4 shared papers)Miao Ding (1 shared paper)Yu Yao (2 shared papers)
- Journals
- Diabetes Metabolic Syndrome and Obesity (3 papers)International Journal of Oncology (1 paper)BMC Women s Health (1 paper)Journal of Dermatological Science (1 paper)The Lancet Diabetes & Endocrinology (1 paper)
- Partner nations
- ChinaSwedenUnited States
In The Last Decade
Ping Tu
31 papers receiving 425 citations
Peers
Comparison fields: 5 of 75
- Endocrinology, Diabetes and Metabolism 107
- Orthopedics and Sports Medicine 32
- Drug Discovery 1
- Nephrology 34
- Cancer Research 28
Countries citing papers authored by Ping Tu
This map shows the geographic impact of Ping Tu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ping Tu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ping Tu more than expected).
Fields of papers citing papers by Ping Tu
This network shows the impact of papers produced by Ping Tu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ping Tu. The network helps show where Ping Tu may publish in the future.
Co-authors
The 25 scholars most cited alongside Ping Tu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 32 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 51 | |
| 2 | 2018 | 41 | |
| 3 | 2014 | 33 | |
| 4 | Xanthatin, a novel potent inhibitor of VEGFR2 signaling, inhibits angiogenesis and tumor growth in breast cancer cells. | 2015 | 30 |
| 5 | 2017 | 28 | |
| 6 | 2019 | 27 | |
| 7 | 2017 | 23 | |
| 8 | 2013 | 21 | |
| 9 | 2022 | 21 | |
| 10 | 2013 | 20 | |
| 11 | 2017 | 20 | |
| 12 | 2013 | 18 | |
| 13 | 2015 | 15 | |
| 14 | 2021 | 15 | |
| 15 | 2015 | 9 | |
| 16 | 2007 | 8 | |
| 17 | 2015 | 7 | |
| 18 | [Effects of lifestyle and quantitative nutrition interventions on individuals with prediabetes]. | 2015 | 6 |
| 19 | 2016 | 6 | |
| 20 | 2018 | 6 |
About Ping Tu
Ping Tu is a scholar working on Endocrinology, Diabetes and Metabolism, Nephrology, Orthopedics and Sports Medicine, Ophthalmology and Cell Biology, having authored 32 papers that have together received 438 indexed citations. Recurring topics across this work include Diabetes, Cardiovascular Risks, and Lipoproteins (6 papers), Chronic Kidney Disease and Diabetes (4 papers), Bone health and osteoporosis research (3 papers), Skin and Cellular Biology Research (3 papers), Phytochemistry and biological activity of medicinal plants (3 papers), Genetic Associations and Epidemiology (3 papers), Blood Pressure and Hypertension Studies (2 papers) and Bone Metabolism and Diseases (2 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (107 citations), Orthopedics and Sports Medicine (32 citations), Drug Discovery (1 citation), Nephrology (34 citations) and Cancer Research (28 citations). Ping Tu has collaborated with scholars based in China, Sweden and United States. Frequent co-authors include Peng Duan, Jiang Liu, Meilin Wei, Yajun Lin, Yong‐Zhan Zhen, Yi Shao, Miao Ding, Yu Yao, Chong-Gang Pei and Jie Wei. Their work appears in journals such as Diabetes Metabolic Syndrome and Obesity, International Journal of Oncology, BMC Women s Health, Journal of Dermatological Science and The Lancet Diabetes & Endocrinology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.